FDA Clearance for Two New Rapid Tests for the Detection of Influenza and RSV
Meridian Bioscience, Inc. (NASDAQ:VIVO) has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market two new upper respiratory tests: TRU FLU ® and TRU RSV ®. These tests are based upon a new rapid test technology that features improved safety and space savings. TRU FLU ® detects both influenza A and influenza B while TRU RSV ® detects for respiratory syncytial virus. These companion tests are ideal for the diagnosis of common upper respiratory diseases.
Source: Meridian Bioscience, Inc. View latest company information
Posted: December 3, 2007
[will open your email client]